Neoplasms Clinical Trial
Official title:
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Verified date | June 2024 |
Source | Theseus Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).
Status | Terminated |
Enrollment | 32 |
Est. completion date | February 2, 2024 |
Est. primary completion date | February 2, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female patient =18 years of age. 2. For Dose Escalation Phase Cohorts (Phase 1): 1. Have histologically- or cytologically-confirmed unresectable or metastatic GIST. 2. Have progressed on or are intolerant to imatinib therapy and have also received at least 1 of the following: sunitinib, regorafenib, ripretinib, or avapritinib. 3. For Expansion Phase Cohorts (Phase 2): 1. Cohort 1: - Have histologically- or cytologically confirmed unresectable or metastatic GIST. - Have progressed on or are intolerant to imatinib, sunitinib, regorafenib and ripretinib. 2. Cohort 2: - Have histologically- or cytologically confirmed unresectable or metastatic GIST. - Have progressed on or are intolerant to imatinib and sunitinib. Patients in this cohort are allowed to have received up to 1 additional line of therapy in the advanced/metastatic setting. 3. Cohort 3: - Have histologically- or cytologically confirmed unresectable or metastatic GIST. - Have progressed on or are intolerant to imatinib (including in the adjuvant setting). - Have not received additional systemic therapy for advanced GIST. 4. Have at least 1 measurable lesion as defined by modified RECIST 1.1. 5. Have archival or new tumor biopsy tissue available to submit for mutational testing. Patients without appropriate archival tissue available may be discussed with the study Medical Monitor and approved for enrollment on a case-by-case basis. 6. Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2. 7. Adequate renal and hepatic function as defined by the protocol. 8. Adequate bone marrow function as defined by the protocol. 9. For female patients of childbearing potential, have a negative serum or urine beta human chorionic gonadotropin (ß-hCG) pregnancy test within 7 days prior to the first dose of study drug. o Note: female patients of nonchildbearing potential (postmenopausal; hysterectomy; bilateral salpingectomy; or bilateral oophorectomy) do not require a pregnancy test. 10. Female patients of childbearing potential must agree to abstain from heterosexual intercourse or use a highly effective form of contraception with their sexual partners as defined in the study protocol. Male patients with partners of childbearing potential must agree that they will abstain from heterosexual intercourse or use condoms and their partners will use highly effective contraceptive methods as defined in the study protocol. 11. All toxicities from prior therapy have resolved to Grade =1 according to NCI CTCAE v5.0, or have resolved to baseline, at the time of first dose of study drug. Note: treatment-related Grade >1 alopecia, treatment related Grade 2 peripheral neuropathy, and treatment-related Grade 2 hypothyroidism on a stable dose of thyroid hormone replacement therapy are allowed if deemed irreversible. 12. Patient or legal guardian, if permitted by local regulatory authorities, signed and dated informed consent indicating that the patient has been informed of all pertinent aspects of the study. 13. Willingness and ability to comply with scheduled visits and study procedures. Exclusion Criteria: 1. Received systemic anticancer therapy (including cytotoxic chemotherapy, investigational agent, antineoplastic monoclonal antibodies, or immunotherapy) less than 5 half-lives or 14 days (whichever is shorter) prior to the first dose of study drug. 2. Patients known to be both KIT and PDGFRA wild-type. 3. Received radiotherapy within 14 days prior to the first dose of study drug. 4. Major surgical procedure within 28 days of the first dose of study drug. Minor surgical procedures such as central venous catheter placement or minimally invasive biopsy are allowed. 5. Have known untreated or active central nervous system metastases. 6. 12-lead electrocardiogram (ECG) demonstrating QT interval corrected by Fridericia's formula (QTcF) >470 msec at screening, or history of long QTc syndrome. 7. Have significant, uncontrolled, or active cardiovascular disease, including, but not restricted to: - Myocardial infarction (MI) within 6 months prior to the first dose of study drug - Unstable angina within 6 months prior to first dose of study drug - Symptomatic congestive heart failure (New York Heart Association classes II-IV) within 6 months prior to first dose of study drug - Clinically significant, uncontrolled atrial arrhythmia (as determined by the Investigator) - Any history of ventricular arrhythmia - Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose of study drug - Uncontrolled hypertension at study entry. Patients with hypertension should be under treatment on study entry to control blood pressure. 8. Have an active uncontrolled infection, including, but not limited to, the requirement for intravenous antibiotics. 9. Patients with a known allergy or hypersensitivity to any component of the study drug. Patients with a history of Stevens-Johnson syndrome on a prior tyrosine kinase inhibitor (TKI) are excluded. 10. Any active bleeding excluding hemorrhoidal or gum bleeding. 11. For patients with a known human immunodeficiency virus (HIV) infection, have CD4+ T-cell counts <350 cells/uL or history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months. Patients with HIV infection should be on established antiretroviral therapy (ART) for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrollment. 12. Has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, as evidenced by detectable viral load (HBV-DNA or HCV-RNA, respectively). Risk of HBV reactivation should be considered in all patients and the need for anti-HBV prophylaxis should be carefully assessed. Patients with chronic HBV infection with history of active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy to be eligible for enrollment. Patients who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible. Patients on concurrent HCV treatment at the time of enrollment are allowed if HCV RNA negative. 13. Pregnant or breastfeeding. 14. Malabsorption syndrome or other illness that could affect oral absorption. 15. Patients with prior or concurrent malignancies other than GIST are allowed, except in the case where, in the opinion of the Investigator, the natural history or treatment of the other malignancy has the potential to interfere with the safety or efficacy assessment of the study drug. 16. Have any condition or illness that, in the opinion of the Investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug. |
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Mayo Clinic Florida | Jacksonville | Florida |
United States | University of Miami Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Oregon Health & Science University | Portland | Oregon |
United States | HonorHealth Research Institute | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Theseus Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose Escalation (Phase 1): Safety Analysis - Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 | Up to 24 months after first dose | ||
Primary | Dose Escalation (Phase 1): Safety Analysis - Number of Participants With Dose-limiting Toxicities (DLTs) Following Oral Administration of THE-630 | 28 days | ||
Primary | Dose Escalation (Phase 1): Safety Analysis - Maximum Tolerated Dose (MTD) of Orally Administered THE-630 | The MTD is defined as the highest dose at which =1 of 6 DLT-assessment eligible patients experience a DLT within the first 28 days of treatment (end of Cycle 1). | 28 days | |
Primary | Dose Escalation (Phase 1): Recommended Phase 2 Dose (RP2D) of Orally Administered THE-630 | The RP2D was expected to be equal to the MTD or less than the MTD, if aspects of tolerability or efficacy not encompassed by the MTD determination suggested utilizing a lower dose. | 28 days | |
Primary | Expansion (Phase 2): Efficacy Assessment - For Each Expansion Phase Cohort (Cohorts 1, 2, and 3), Confirmed Objective Response Rate (ORR), According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | Up to 24 months after first dose | ||
Secondary | Dose Escalation (Phase 1): Plasma Pharmacokinetic (PK) Parameters of THE-630 and Its Active Metabolite - Cmax (Maximum Observed Concentration) | Cmax of THE-630 and its active metabolite after single oral dose and at steady state after multiple oral doses | Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 28 days) | |
Secondary | Dose Escalation (Phase 1): Plasma PK Parameters of THE-630 and Its Active Metabolite - Tmax (Time of First Occurrence of Cmax) | Tmax of THE-630 and its active metabolite after single oral dose and at steady state after multiple oral doses | Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 28 days) | |
Secondary | Dose Escalation (Phase 1): Plasma PK Parameters of THE-630 and Its Active Metabolite - AUC 0-24 (Area Under the Concentration-time Curve From Time Zero to 24 Hours) | AUC 0-24 of THE-630 and its active metabolite after single oral dose and at steady state after multiple oral doses | Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 28 days) | |
Secondary | Dose Escalation (Phase 1): Plasma PK Parameters of THE-630 and Its Active Metabolite - AUC 0-t (Area Under the Concentration-time Curve From Time Zero to Time t) | AUC 0-t of THE-630 and its active metabolite after single oral dose and at steady state after multiple oral doses | Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 28 days) | |
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Confirmed ORR, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Best Overall Response, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Best Target Lesion Response, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Time to Response, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Duration of Response (DOR), According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Disease Control Rate (DCR), According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Clinical Benefit Rate (CBR) at 16 Weeks, According to Modified RECIST 1.1 | 16 weeks | ||
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Progression Free Survival (PFS), According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Dose Escalation (Phase 1): Efficacy Assessment - Overall Survival (OS) | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Efficacy Assessment - Best Overall Response, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Efficacy Assessment - Best Target Lesion Response, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Efficacy Assessment - Time to Response, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Efficacy Assessment - DOR, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Efficacy Assessment - DCR, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Efficacy Assessment - CBR at 16 Weeks, According to Modified RECIST 1.1 | 16 weeks | ||
Secondary | Expansion (Phase 2): Efficacy Assessment - PFS, According to Modified RECIST 1.1 | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Efficacy Assessment - OS | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Safety Analysis - Number of Participants With Treatment-emergent Adverse Events as Assessed by NCI CTCAE v5.0 | Up to 24 months after first dose | ||
Secondary | Expansion (Phase 2): Plasma PK Parameters of THE-630 and Its Active Metabolite - Cmax (Maximum Observed Concentration) | Cmax of THE-630 and its active metabolite after single oral dose and at steady state after multiple oral doses | Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 28 days) | |
Secondary | Expansion (Phase 2): Plasma PK Parameters of THE-630 and Its Active Metabolite - Tmax (Time of First Occurrence of Cmax) | Tmax of THE-630 and its active metabolite after single oral dose and at steady state after multiple oral doses | Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 28 days) | |
Secondary | Expansion (Phase 2): Plasma PK Parameters of THE-630 and Its Active Metabolite - AUC 0-24 (Area Under the Concentration-time Curve From Time Zero to 24 Hours) | AUC 0-24 of THE-630 and its active metabolite after single oral dose and at steady state after multiple oral doses | Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 28 days) | |
Secondary | Expansion (Phase 2): Plasma PK Parameters of THE-630 and Its Active Metabolite - AUC 0-t (Area Under the Concentration-time Curve From Time Zero to Time t) | AUC 0-t of THE-630 and its active metabolite after single oral dose and at steady state after multiple oral doses | Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 28 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |